P&G Call Buyers Push PCR to a One-Month Extreme

Procter & Gamble options are running their most call-heavy in over a month. The put/call ratio hit 0.6247 on October 27, sitting 2.1 standard deviations below its 20-day mean of 0.7051. The 52-week low is 0.588, so the current reading is near the bullish end of the full-year range.

The shift comes as the rest of the positioning picture continues to lighten. Every friction point that existed ahead of the October 22 earnings print has since dissolved.

The Short Side Has Effectively Closed

Short interest stood at 0.92% of the free float as of October 26, a cumulative drop of 24% over the past month. The daily rate fell 11.9% on October 26 alone. At this level, the short position is statistical noise for a company with a $369 billion market cap.

The borrow market reflects the same picture. Cost to borrow fell to 0.08%, down 76% in one week. Availability is at 9,999% of short interest, meaning the pool of shares available to lend dwarfs what is actually borrowed by a factor of roughly 100. There is no friction on the short side because there are almost no short sellers left.

Analysts Still Moving Targets Higher

The analyst action has not stopped since earnings. Barclays raised its target to $165 from $152 on October 26. Piper Sandler moved to $167 from $145 the same day. Both maintained neutral ratings. UBS holds the high-water mark at $190.

The consensus mean target stands at $173.30. The stock closed October 27 at $159.23. That gap is roughly 8.8%.

Capital Research and Management added 6.4 million shares as of the last reported period. Charles Schwab Investment Management added 3.5 million. BlackRock added nearly 3 million. The institutional flow is pointing the same direction as the options market.

What the CEO Did on Earnings Day

One note of contrast. Chairman and CEO Shailesh Jejurikar sold 35,000 shares on October 23 at $163.09, a transaction worth $5.7 million. The sale was not filed under a pre-arranged 10b5-1 plan. He simultaneously exercised options on 35,000 shares at $78.52. The net cash outlay on the exercise was covered by the sale, a common equity management practice, though the absence of a 10b5-1 disclosure is worth registering. The 90-day net insider position across all transactions stands at minus $12.9 million.

The CEO's disposal sits alongside a week in which every other positioning signal moved toward the constructive side. The borrow market is frictionless, options traders favour calls by a historically wide margin, shorts have cut exposure by a quarter over the month, and the Street raised price targets at eight firms inside 72 hours after the print.

---

Data summary

• PCR: 0.6247, z-score minus 2.09, 52-week low is 0.588
• SI % of free float: 0.92%, down 24% over one month
• Cost to borrow: 0.08%, down 76% on the week
• Borrow availability: 9,999% of short interest
• Consensus mean price target: $173.30 vs close of $159.23
• CEO open-market sale: 35,000 shares at $163.09 on October 23, no 10b5-1 plan declared
• 90-day net insider value: minus $12.9 million